PT - JOURNAL ARTICLE AU - Jyotirmayee Lenka AU - Mamta S. Chhabria AU - Naman Sharma AU - Bryan E-Xin Tan AU - Leela Krishna Teja Boppana AU - Sharini Venugopal AU - Damanpaul S. Sondhi TI - Clinical characteristics and outcomes of critically ill patients with COVID-19 in a tertiary community hospital in upstate New York AID - 10.1101/2020.06.18.20135046 DP - 2020 Jan 01 TA - medRxiv PG - 2020.06.18.20135046 4099 - http://medrxiv.org/content/early/2020/06/22/2020.06.18.20135046.short 4100 - http://medrxiv.org/content/early/2020/06/22/2020.06.18.20135046.full AB - Background There are limited reports describing critically ill COVID-19 patients in New York.Methods We conducted a retrospective analysis of 32 adult critically ill patients admitted to a tertiary community hospital in upstate NY, between March 14th and April 12th, 2020. We collected demographic, laboratory, ventilator, and treatment data, which were analyzed and clinical outcomes tabulated.Results 32 patients admitted to the ICU were included, with mean (±SD) follow-up duration 21 ± 7 days. Mean (±SD) age was 62.2 ± 11.2 years, and 62.5% were men. 27 (84.4%) of patients had one or more medical co-morbidities and 50% of the patients were current or former smokers. The mean (±SD) duration of symptoms was 6.6 (±4.4) days before presentation, with cough (81.3%), dyspnea (68.7%), and fever (65.6%) being most common. 23 (71.9%) patients received invasive mechanical ventilation. 5 (15.6%) had died, 11 (34.4%) had been discharged home, and 16 (50%) remained hospitalized, 8 (25%) of which were still in ICU. Mean (±SD) length of ICU stay was 10.2 (±7.7) days, and mean (±SD) length of hospital stay was 14.8 (±7.7) days.Conclusion Majority of patients were of older age and with medical co-morbidities. With adequate resource utilization, mortality of critically ill COVID-19 patients may not be as high as previously suggested.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding sourceAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Rochester Regional Health (RRH) Institutional Review Board approved our case series (IRB:1982A). Informed consent was waived and researchers analyzed only de-identified data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe collected demographic, clinical, laboratory, radiological, ventilator and treatment data by manual review of electronic medical records (EPIC EMR) of patients admitted to our medical intensive care unit. The data was then de-identified, prior to analysis.ACE-iAngiotensin converting enzyme inhibitorARBAngiotensin receptor blockerARDSAcute Respiratory Distress SyndromeBiPAPBilevel positive airway pressureCABGCoronary artery bypass graftCFRCase fatality rateCOVID-19Coronavirus disease 19CPAPContinuous positive airway pressureCRPC – Reactive ProteinCTComputed tomographyDVTDeep vein thrombosisECMOExtra Corporeal Membrane OxygenationESICMEuropean Society of Intensive Care MedicineFiO2Fraction of inspired O2HFNCHigh Flow Nasal CannulaHITFHypoxia-Inducible Transcription FactorIBMInternational Business MachinesICUIntensive Care UnitILInterleukinIMVInvasive Mechanical VentilationIQRInterquartile RangeISTHInternational Society of Thrombosis HemostasisNIVNon Invasive VentilationNYNew YorkPAIPlasminogen activator inhibitorPaO2partial pressure of arterial oxygenPCVPressure Control VentilationPEEPPositive End Expiratory PressureRGHRochester General HospitalRRHRochester Regional HealthRT-PCRReverse transcriptase polymerase chain reactionRSVRespiratory Syncytial virusSARS-CoV-2Severe Acute Respiratory Syndrome Coronavirus 2SDStandard DeviationSTEMIST segment elevation myocardial infarctionTNFTumor necrosis factorUSAUnited States of AmericaVTEVenous thromboembolism